Researchers at the University of South Florida USF Health Morsani College of Medicine have identified a potential pathway ...

Sonothera is developing a new way to deliver genes into cells that, if borne out, could have a big impact on muscular ...

PHILADELPHIA, May 14, 2026 /PRNewswire/ -- Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting ...

The most commonly diagnosed form of muscular dystrophy, Duchenne is a genetic disease that affects mostly boys and causes progressive muscle weakness over time. Its early physical signs tend to be ...

The Food and Drug Administration (FDA) has approved the first gene therapy for the treatment of Duchenne muscular dystrophy (DMD) in children from age 4 through 5 years of age. Pediatric patients who ...

DUBLIN--(BUSINESS WIRE)--The "Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of ...

In the open-label study, DMD patients received Satellos’ oral drug for an additional 11 months, following an earlier 28-day trial.

New market intelligence highlights therapeutic innovation, expanding treatment access and strategic investment as key drivers of global growth. Duchenne Muscular Dystrophy Treatment Market Duchenne ...

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Delandistrogene moxeparvovec ...

LONDON--(BUSINESS WIRE)--The global Duchenne muscular dystrophy (DMD) therapeutics market size is poised to reach USD 2.23 billion by 2023, according to a new report by Technavio, progressing at a ...